Leadership Team

Our highly collaborative team has internationally recognized expertise in every aspect of our work, with a proven track record of success in all areas.

Executive Team

Dr. Peter Silverstone

Chief Executive Officer & Director

Dr. Silverstone has a 35 year background in brain and pharmaceutical research. He has been involved in the successful development of multiple health related start ups.

Dr. Silverstone was Senior Vice President, Medical and Scientific Affairs, of Biovail; a large publicly traded pharmaceutical company with over a billion dollars of sales. He has highly relevant expertise in international drug and IP development and regulatory issues.  Dr. Silverstone is a Professor in the Department of Psychiatry at the University of Alberta.

Dr. Silverstone received both his MD and PhD from the University of London. He spent 3 years as a research fellow at the University of Oxford studying psychopharmacology. Dr. Silverstone's research achievements have won several awards, including the Alberta Heritage Foundation for Medical Research and the Queen Elizabeth II Diamond Jubilee Medal.

Louise Duchesne, CPA, CA

Chief Financial Officer

Ms. Duchesne is a co-founder and managing director of Lightyear Capital Inc., a Calgary-based investment dealer and is responsible for the oversight of the firm. Ms. Duchesne brings over 30 years of financial accounting, tax, regulatory compliance, capital markets, and investment industry experience.

Prior to co-founding Lightyear, Ms. Duchesne was the Chief Financial Officer & Director of an independent, fully integrated investment dealer, and previously a manager in the assurance group with Ernst & Young, LLP.

 

Ms. Duchesne holds a Bachelor of Commerce degree from McGill University, a CPA, CA designation and is a member of the Chartered Professional Accountants of Alberta.

Scott Phillips, MBA, CPA, CA
Chief Operating Officer

Mr. Phillips has over 20 years experience in operations. Most recently, he is Assistant Chair, for the Department of Psychiatry at the University of Alberta,

where he works directly with mental health education and  service delivery. Prior to that, he led the logistics network for the nation's 3rd largest private lab, with a team of over 65 employees and contracts covering Western Canada.

He has led multi million dollar start ups, with focus on both the national and international markets; specifically in the technology and fabrication space. He obtained his MBA from Cornell University and maintains a CPA/CMA designation, as well as a PMP designation. In 2019, Mr. Phillips was named one of the Top 40 under 40 in Edmonton. He is currently the Chair for the CASA Foundation and Director at Our House, a male addiction recovery centre.

Mycology Team

.

.

.

Dr. James Scott
VP, Mycology Development

Dr. James Scott is the Founder, Owner, and Chief Scientific Officer of Sporometrics, world-leading mycology group. His PhD in Mycology was earned through the Department of Botany at the University of Toronto in 2001 studying the ecology and systematics of fungi in house dust. He is an internationally recognized expert on fungi associated with humans, animals, and their environments.

 

Dr. Scott is a Professor and Division Head of Occupational & Environmental Health at the Dalla Lana School of Public Health at the University of Toronto, and the Director of the UAMH Centre for Global Microfungal Biodiversity, which is the largest repository of living strains of environmental and biomedically important fungi in the western hemisphere. He also serves as a mycology consultant on mushroom poisoning to the Ontario Poison Centre.

 

Dr. Scott's teaching and research deals with bioaerosols, fungal systematics and life-cycle biology, and the microbiome of humans and the built environment. Dr. Scott is working exclusively with PsiloTec on the development of novel therapeutic mushrooms.

Robert Rogers
Lead, Research & Formulation

Robert Rogers has built, over five decades, an international reputation for the promotion of medical mushrooms. He has been a clinical herbalist for nearly 50 years, and is presently a clinical professor in family medicine at the University of Alberta, and adjunct professor in graduate studies at York University.


Mr. Rogers has published over 50 books on plant and mushroom medicine including The Fungal Pharmacy:  The Complete Guide to Medicinal Mushrooms and Lichens of North America. And in 2020, he published Medicinal Mushrooms: The Human Clinical Trials. Robert taught plant and mushroom medicine for over ten years at Grant McEwan University, and various colleges over past thirty years. He has formulated for various companies in the natural health industry, including supplement lines, and nutraceutical food bars. Robert previously chaired the Alberta Natural Health Agricultural Network, and Capital Health Community Health Council, and served on the editorial board of the International Journal of Medicinal Mushrooms for a number of years.

Today he presents at conferences on medicinal mushrooms throughout North America and Europe and is actively involved with all aspects of PsiloTec’s mycology program and development of unique mushroom strains.

 
 
 
 
 

Tradd Cotter

Advisor, Mycology Enhancement

 

Mr. Cotter is a microbiologist, professional mycologist, and organic gardener, who has been tissue culturing, collecting native fungi in the Southeast US, and cultivating both commercially and experimentally for more than 22 years. Mr. Cotter lectures throughout North America, focusing his efforts on perpetual methods of mushroom cultivation.

 

Mr. Cotter has undertaken numerous studies to explore applications for mushrooms in various industries and currently maintains over 200 species of fungi for food production and mycoremediation of environmental pollutants.

He has been the focus of interviews and documentaries in various media, including National Geographic.

Mr. Cotter is the Designer/Chief Instructor of the North American Wild Mushroom Safety Certification Program, Designer/Chief Instructor and the North American Mycological Association Emergency Mushroom Toxicology Contact.

e-Clinics Team

 

.

.

.

Dr. Pierre Chue
Advisor, Medical Affairs

Dr. Chue has extensive experience in psychopharmacology. As the Director of the Clinical Trials and Research Program, Edmonton, he has been involved in over 50 clinical trials in areas including depression, anxiety disorders and addiction. Dr. Chue is a researcher with the Integrative Health Institute, Centre of Excellence for Real World Clinical Outcomes and Campus Alberta Neuroscience (University of Alberta).

 

Dr. Chue completed his medical degree (MBBCh) and psychiatric specialization (MRCPsych) in the UK before moving to Canada in 1991 where he subsequently obtained Canadian medical (LMCC) and specialist qualifications (FRCPC) as well as American Boards Certification in Psychiatry and Neurology (DABPN) and an MSc in Psychiatry at the University of Alberta. He was elected a Fellow of the Royal College of Psychiatrists (FRCPsych) in the UK in 2004.

Dr. Matthew Brown

Vice President, Technology

 

Dr. Brown is a leading researcher in mental health and computational psychiatry, applying artificial intelligence to mental health, with publications in Nature Research Journals in 2017 and 2019. He is also the co-founder of Retain Labs Medical Incorporated and DynaGenium Bioimplants Inc.

 

Dr. Brown received his PhD in Neuroscience from the University of Western Ontario. He has a strong background in neuroscience, machine learning / artificial intelligence, computational psychiatry, project management of clinical studies, and brain imaging techniques. 

Dr. Brown is an Adjunct Professor in the Department of Computing Science at the University of Alberta, working in the world-class artificial intelligence group at the University of Alberta. 

Dr. Hannah Pazderka
Consultant

 

Dr. Pazderka has been working in mental health research within the field of psychiatry for over 25 years. She received her PhD in Neuroscience from the University of Alberta in 2004, examining indices of drug and alcohol craving. She is knowledgeable in a  number of different assessment and analysis methodologies, including structural equation modeling, psychophysiology (ERPs and skin conductance), neuropsychological assessment, and epidemiology.

 

Dr. Pazderka has worked in a number of roles, including creation of public policy, research, and advocacy. Her primary research interests are in the regulation of reward seeking and impulsive behaviour via the frontostriatal reward system, particularly in response to trauma.

Lee-Ann Langkaas
Senior Clinical Trials Manager

 

Lee-Ann  has over 20 years of clinical trials experience in multiple areas including project management, regulatory compliance, and management of complex clinical studies in multiple areas.

Lee-Ann has strong financial clinical trials expertise ensuring that they are carried out in the most cost-effective manner. Lee-Ann was working as a Research Manager with an internationally recognized expert group of researchers at the University of Alberta. She has significant experience in interactions with clinical investigators, pharmaceutical sponsors and regulatory agencies. 

Lee-Ann holds accreditations from numerous clinical trials organizations.

Board of Directors

.

.

.

 

Murray Weimer, CPA, CA
Chairman

Mr. Weimer is a co-founder and managing director of Lightyear Capital Inc., where he oversees all aspects of Lightyear’s investment banking initiatives and Lightyear’s merchant banking division.

 

Over Mr. Weimer’s 25 year career he has supported the start up and growth of multiple companies in a diverse range of business lines and has executed on numerous M&A, valuation, equity and debt financing assignments.

As Chairman of PsiloTec, Mr. Weimer is actively involved in all aspects of PsiloTec’s business strategy along with providing leadership on executing PsiloTec’s capital markets strategy.

Mr. Weimer holds a Bachelor of Commerce degree from the University of Saskatchewan, a CPA, CA designation and is a member of the Chartered Professional Accountants of Alberta.

James Mish
Director

Mr. Mish is currently the CEO of 22nd Century Group, Inc. (NYSE AMEX XXII), a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene editing and

modern plant breeding. 

He has an outstanding 35 year track record of delivering profitable growth at both privately held and publicly traded science driven companies with a focus on pharmaceutical and consumer products. Prior to joining 22nd Century, Mr. Mish served as President and CEO of Purisys, a synthetic cannabinoid API, ingredients and solutions provider to pharmaceutical and consumer products companies, and Noramco, a global leader in the production of controlled substances for the pharmaceutical industry.

Mr. Mish is a graduate from the Pennsylvania State University in Chemistry and The University of Pennsylvania, Wharton School of Business.

 

Dr. Richard Summerbell
Director

 

Dr. Richard Summerbell is one of the world’s foremost experts on fungi affecting human and environmental health. He is the author of over 180 peer reviewed scientific papers on fungi and bacteria, and has co-authored two popular laboratory manuals, “Identifying Fungi” and “Laboratory Handbook of Dermatophytes”. 

Dr. Summerbell is currently an Associate Professor of Occupational & Environmental Health at the Dalla Lana School of Public Health at the University of Toronto, and Research Director at Sporometrics, world-leading mycology group. Previously, Dr. Summerbell spent a decade as Chief of Medical Mycology at the Ontario Ministry of Health Central Public Health Lab, followed by 6 years as a Senior Scientist and Group Leader at the Centraalbureau voor Schimmelcultures (now the Westerdijk Institute), the world premier mycological institute and a branch of the Royal Dutch Academy of Sciences in Utrecht, The Netherlands.

Dr. Peter Silverstone
Chief Executive Officer & Director

 

Corporate Support Team

.

.

.

Dr. Silverstone has a 35 year background in brain and pharmaceutical research. He has been involved in the successful development of multiple health related start ups.

Dr. Silverstone was Senior Vice President, Medical and Scientific Affairs, of Biovail; a large publicly traded pharmaceutical company with over a billion dollars of sales. He has highly relevant expertise in international drug and IP development and regulatory issues.  Dr. Silverstone is a Professor and currently Interim Chair of the Department of Psychiatry at the University of Alberta.

Dr. Silverstone received both his MD and PhD from the University of London. He spent 3 years as a research fellow at the University of Oxford studying psychopharmacology. Dr. Silverstone's research achievements have won several awards, including the Alberta Heritage Foundation for Medical Research and the Queen Elizabeth II Diamond Jubilee Medal.

 

Cori White
Senior Marketing Consultant

For over 25 years Ms. White has been working in marketing with both large and small companies developing a wide variety of consumer-focused product offerings. Past clients include Pepsi-Cola, McDonald's, Cara Operations (Harvey’s Restaurants), AGLC and multiple others. Marketing budgets she has managed and directed have been up to $25 million.

 

Ms. White has been very active in terms of social media marketing  and manages all aspects of marketing including working closely with appropriate sales channels and creative partners. 

 

Over the past 8 years she has also been actively involved with  marketing initiatives for multiple groups in the mental health area, including both for-profit start-ups and not-for-profit organizations.

John Rajman
Security Consultant

 

Mr. Rajman has over 24 years experience in public safety and has collaborated with both foreign and domestic governments on security considerations for personnel and high risk infrastructure.

Mr. Rajman has led tactical operations for federal protective task forces, national security, and counterterrorism. He has also trained law enforcement personnel across Canada and abroad on specialized tactics including U.S. Department of Homeland Security sponsored training for local, state, and national agencies. He has planned and deployed on multiple overseas missions to high-risk countries, providing tactical support for the highest levels of government leadership while maintaining the integrity of targeted and vulnerable infrastructure.

 

As a leading subject matter expert on threat assessment and analysis, Mr. Rajman leads all determination for security of PsiloTec products and transportation.